All News

COVID vaccine vials

Comparison of Three Coronavirus Vaccines

d Jack Cush, MD

On Feb. 27, the Food and Drug Administration announced it has issued an emergency use authorization for Johnson & Johnson’s one-dose Covid vaccine, making it the third COVID-19 vaccine to be commercially available.  We've compiled a comparison table and some key information relevant to your delivering patient guidance henceforth. 

Read Article
vaccination.jpg

CDC: Interim Guidance for COVID Vaccinated People

d Jack Cush, MD

Among 330 million Americans, roughly 32.1 million have been fully vaccinated and 61.1 million have received at least one dose of a COVID-19 vaccine (as of March 8th).

Read Article
colitis.jpg

Low IBD Risk with IL-17 Inhibition

d Jack Cush, MD

Incident or worsening colitis is a rare complication of IL-17 inhibitor therapy; a real world study confirms very low rates of new IBD in patients starting secukinumab.

Read Article
Lungs ILD

Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease

d Jack Cush, MD

Genentech announced Thursday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adul

Read Article
QD Clinic - Ms. RA Can Multiple Sclerosis and RA Coexist? What Drugs can be used? https://t.co/PYFQI7vn3M

Links:

Dr. John Cush RheumNow ( View Tweet)

Analysis of US National Inpatient Sample (2000‐2014). In #RA pts, there was a signif decline in annual rate of hospitalizations (76per million in 2000 to 30 per million 2014) & Hosp mortality (0.70% to 0.41%); but a signif incr in hosp for arthroplasty https://t.co/kkpmdKzEhQ

Links:

Dr. John Cush RheumNow ( View Tweet)

75 RA pts on MTX >3 yrs had FIBROSCANS done to assess their value. 12 pts (16%) had Fibroscan ≥ 7.1 kPa, 3 patients w/ severe liver stiffness (9.5 to 12.5 kPa) & 1 w/ cirrhosis range scores (> 12.5 kPa). No Bx were done; LFTs were not predictive https://t.co/Pi1h1nF0Uq

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: CDC: Interim Guidance for COVID Vaccinated People https://t.co/3GZDCVF0hv https://t.co/qyQyajjqM8

Links:

Dr. John Cush RheumNow ( View Tweet)
2020 Year in Review - Top Publications in SpA and Still’s Disease Sponsored by Novartis Medical Affairs Listen to medical experts discuss their latest insights in spondyloarthritis and Still’s disease. View Now: https://t.co/rxTAwQNalx https://t.co/bmjrEdkf89

Links:

Dr. John Cush RheumNow ( View Tweet)
Matched cohort study f142 Takayasu arteritis pts - incidence 0.8 per million/Yr. TAK had increased in All‐cause mortality (adj HR 1.88 ;1.29–2.76), ischemic heart dz, CVA, TIA, CVD, PVD - but not HTN, CHF or DM. Only ~50% were on statins or anti-Plt Rx https://t.co/rgNqkha6sq

Links:

Dr. John Cush RheumNow ( View Tweet)

Swedish registry looked at odds of achieving remission with either Triple DMARD (347 MSH) or biologic Rx (1155) - more pts on biologics achieved remission at 1 yr (OR 1.79;1.18‐2.72) and 2 yrs (OR 1.92;1.21‐3.06). https://t.co/1MwhDbNxbf

Links:

Dr. John Cush RheumNow ( View Tweet)

Analysis of 8416 pts w/ Kawasaki disease (KD) shows older and younger children differ. <10% were under 6 mos, 78%) were 6 mos-4yrs; 11% 5 to 9 yrs. Younger KD had more incomplete KD, coronary aneurysms, while older had more delayed diagnoses, more fever https://t.co/NkSmfg38ru

Links:

Dr. John Cush RheumNow ( View Tweet)

The Reflecting Rheum: 2020 SpA and Still’s Disease Highlights Sponsored by Novartis Medical Affairs Listen to a discussion of medical experts share their views on the most impactful work done in spondyloarthritis and Still’s disease in 2020. https://t.co/rxTAwQNalx https://t.co/OEbHRn3gKP

Links:

Dr. John Cush RheumNow ( View Tweet)
Blinded by Noncompliance--New QD Clinic Suggestions on Optimizing Compliance in the Clinic https://t.co/tBnjBX68O8 https://t.co/uZ3aA7bnTJ

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Low IBD Risk with IL-17 Inhibition https://t.co/1kUH7sP755 https://t.co/DypPAcxB2a

Links:

Dr. John Cush RheumNow ( View Tweet)
Data Safety committee has closed recruitment to the colchicine arm in the RECOVERY trial a UK study of outcomes in COVID-19. Among 11162 enrolled pts (2178 deaths) those Rx w/ Colchicine had same 28 day mortality as usual care (20% vs. 19%) https://t.co/8gUc8LAZTp

Links:

Dr. John Cush RheumNow ( View Tweet)

Not surprisingly, a trial of repetitive transcranial magnetic stimulation failed to improve pain in fibromyalgia - next we can look forward to eye of newt N-of-1 trials. https://t.co/mEvvZhYgyR

Links:

Dr. John Cush RheumNow ( View Tweet)

We are just two weeks out from RheumNow Live. There's still time to register. Attend virtually or in-person. CME credits available. https://t.co/3zMtzt4t2H https://t.co/09Q5rRXsst

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast – Pounds of Prevention Dr. Jack Cush Reviews the news and journal reports from the past week on RheumNow. This podcast is sponsored by RheumNow Live. https://t.co/4XSBysiVFW https://t.co/PREqOkyuM9

Links:

Dr. John Cush RheumNow ( View Tweet)
Population study from Southern Norway shows the incidence of giant cell arteritis is not increasing. Over 13yrs, from pop of 300k they identified 206 GCA pts (72%females). Incidence rate of 16.8/100k per year. Mortality was not increased https://t.co/UA16uIuwD1

Links:

Dr. John Cush RheumNow ( View Tweet)

×